Analyst Price Target is $6.13
▲ +525.00% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Theratechnologies in the last 3 months. The average price target is $6.13, with a high forecast of $9.00 and a low forecast of $3.25. The average price target represents a 525.00% upside from the last price of $0.98.
Current Consensus is
The current consensus among 3 investment analysts is to buy stock in Theratechnologies.
Theratechnologies, Inc. is a pharmaceutical company, which engages in addressing medical needs of patients with Human Immunodeficiency Virus (HIV). The firm offers its product under the brand name of EGRIFTA, which is an approved therapy for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. The company was founded on October 19, 1993 and is headquartered in Montréal, Canada.